Anmol Kumar AK, KK Pulicherla KKP, K. Seetha Ram KSR, KRS Sam
basiva Rao KRSSR. Evolutionary trend of thrombolytics. Int J Bio Sci Bio Technol 2010; 2:51-68.
2. Banerjee A, Chisti Y, Banerjee UC. Streptokinase--a clinically useful thrombolytic agent. Biotechnol Adv 2004; 22:287-307.
3. Kunamneni A, Abdelghani TTA, Ellaiah P. Streptokinase—the drug of choice for thrombolytic therapy. J Thromb Thrombolysis. 2007; 23:9-23.
4. Baruah DB, Dash RN, Chaudhari M, Kadam S. Plasminogen activators: A comparison. Vasc Pharmacol 2006; 44:1-9.
5. Della G, Miocardico SNI. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990; 336:65-71.
6. Ridker PM, O’Donnell C, Marder VJ, Hennekens CH. Large-scale trials of thrombolytic therapy for acute myocardial infarction: GISSI-2, ISIS-3, and GUSTO-1. Ann Int Med 1993; 119:530.
7. Sikri N, Bardia A. A history of streptokinase use in acute myocardial infarction. Texas Heart Institute J 2007; 34:318-327.
8. Abdelghani TTA, Kunamneni A, Ellaiah P. Isolation and mutagenesis of streptokinase producing bacteria. Am J Immunol 2005; 1:125-129.
9. Arabi R, Roohvand F, Noruzian D, sardari S, Aghasadeghi MR, Khanamad H,
et al
. A comparative study on the activity and antigenicity of truncated and full-length forms of streptokinase. Polish J Microbiol 2011; 60:243-252.
10. Malke H. Polymorphism of the streptokinase gene: implications for the pathogenesis of post-streptococcal glomerulonephritis. Zentralblatt für Bakteriologie. Int J Med Microbiol 1993; 278:246- 253.
11. Malke H, Steiner K, Gase K, Mechold U, Ellinger T. The streptokinase gene: allelic variation, genomic environment and expression control. Dev Biol Stand 1995; 85:183.
12. Pupo E, Baghbaderani BA, Lugo V, Fernández J, Páez R, Torréns I. Two streptokinase genes are expressed with different solubility in Escherichia coli W3110. Biotechnol lett 1999; 21:1119-1123.
13. Keramati M, Roohvand F, Eslaminejad Z, Nikbin VS, Aslani MM. PCR/RFLP-based allelic variants of streptokinase and their plasminogen activation potencies. FEMS Microbiol Lett 2012; 335:79- 85.
14. Tewodros W, Norgren M, Kronvall G. Streptokinase activity among group A streptococci in relation to streptokinase genotype, plasminogen binding, and disease manifestations. Microbial Pathogenesis 1995; 18:53-65.
15. Al Sohaimy S, Aleem E, Hafez EE, Esmail SS, El-Saadani M, Moneim NA. Expression of recombinant Streptokinase from local Egyptian Streptococcus sp. SalMarEg. Afr J Biotechnol 2011; 105:9001- 9011.
16. Freeda F. Production and partial purification of streptokinase by streptococcus sp. Int J Students Project (IJSP)-Biotechnol 2010; 1:1-39.
17. Doss HM, Manohar M, Singh NA, Mohanasrinivasan V, Devi CS. Studies on isolation, screening and strain improvement of streptokinase producing -hemolytic streptococci. World J Sci Technol 2011; 1:7-11.
18. Garrity GM, Brenner DJ, Krieg NR. Bergey’s manual of systematic bacteriology. Springer; 2005.
19. Kim DM, Lee SJ, Kim IC, Kim ST, Byun SM. Asp41-His48 region of streptokinase is important in binding to a substrate plasminogen. Thrombosis Res 2000; 99:93-98.
20. Sambrook J, Russell DW. The condensed protocols from molecular cloning: a laboratory manual: Cold Spring Harbor Laboratory
619
Pr; 2006; 8.
21. Crowe J, Henco K. The QIAexpressionist. DIAGEN GmbH, Hilden, Germany: 1992.p.2.
22. Ingham KC. Precipitation of proteins with polyethylene glycol. Methods Enzymol 1990; 182:301-306.
23. Wohl RC, Summaria L, Robbins K. Kinetics of activation of human plasminogen by different activator species at pH 7.4 and 37 degrees C. J Biologic Chem 1980; 255:2005-2011.
24. Wu XC, Ye R, Duan Y, Wong SL. Engineering of plasmin-resistant forms of streptokinase and their production in Bacillus subtilis: streptokinase with longer functional half-life. App Environ Mi�crobiol 1998; 64:824-830.
25. Pimienta E, Ayala JC, Rodríguez C, Ramos A, Van Mellaert L, Vallín C,
et al
. Recombinant production of Streptococcus equisimilis streptokinase by Streptomyces lividans. Microb Cell Fact 2007; 6:20-31.
26. Sands D, Whitton C, Longstaff C. International collaborative study to establish the 3rd International Standard for Streptokinase. J Thromb Haemost 2004; 2:1411-1415.
27. Winn WC, Koneman EW. Koneman’s color atlas and textbook of diagnostic microbiology. Lippincott williams & wilkins; 2006.
28. Hughes JM, Wilson ME, Brandt CM, Spellerberg B. Human infections due to Streptococcus dysgalactiae subspecies equisimilis. Clin Infect Dis 2009; 49:766-772.
29. Barnham M, Kerby J, Chandler R, Millar M. Group C streptococci in human infection: a study of 308 isolates with clinical correlations. Epidemiol Infect 1989; 102:379-390.
30. Davies MR, McMillan DJ, Sriprakash KS, Chhatwal GS. Distribution of group A streptococcal virulence genes in group C and G streptococci. Int Cong Series 2006; 1289:184-187.
31. Steiner K, Malke H. Dual control of streptokinase and streptolysin S production by the covRS and fasCAX two-component regulators in Streptococcus dysgalactiae subsp. equisimilis. InfectImmun. 2002; 70:3627-3636.
32. Kim MR, Choeng YH, Chi WJ, Kang DK, Hong SK. Heterologous production of streptokinase in secretory form in streptomyces lividans and in nonsecretory form in escherichia coli. J Microbiol Biotechnol 2010; 20:132-137.
33. Balagurunathan B, Ramchandra NS, Jayaraman G. Enhancement of stability of recombinant streptokinase by intracellular expression and single step purification by hydrophobic interaction chromatography. Biochem Engineering Journal. 2008;39(1):84- 90.
34. Longstaff C, Thelwell C, Whitton C. The poor quality of streptokinase products in use in developing countries. J Thromb Haemost 2005; 3:1092-1094.
)